drugset / Trial / NCT07120698
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Phase 2
Recruiting
115 enrolled
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital · collabShenzhen Second People's Hospital · collabSuining Central Hospital · collabZunyi Medical College · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.
Timeline
- Start
- 2025-11-05
- Primary completion
- 2029-06-26
- Completion
- 2029-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |